tiprankstipranks
Advertisement
Advertisement

SRPT Stock Latest News

Private Markets: Cursor in talks for $2B, Blue Energy secures $380M
The FlyPrivate Markets: Cursor in talks for $2B, Blue Energy secures $380M
7d ago
BA
BE
Roche decision could hurt Sarepta in U.S., says H.C. Wainwright
PremiumThe Fly
Roche decision could hurt Sarepta in U.S., says H.C. Wainwright
14d ago
CHRO
SRPT
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
PremiumThe Fly
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
17d ago
DYN
RNA
Sarepta price target raised to $19 from $18 at RBC Capital
PremiumThe Fly
Sarepta price target raised to $19 from $18 at RBC Capital
23d ago
SRPT
Deutsche ups Sarepta target, says 35% stock rally overdone
PremiumThe Fly
Deutsche ups Sarepta target, says 35% stock rally overdone
1M ago
SRPT
Sarepta price target raised to $35 from $29 at Wedbush
PremiumThe FlySarepta price target raised to $35 from $29 at Wedbush
1M ago
SRPT
Sell Rating on Sarepta: Strong siRNA Muscle Exposure Undermined by Weak Clinical Validation and ELEVIDYS Sales Risk
Premium
Ratings
Sell Rating on Sarepta: Strong siRNA Muscle Exposure Undermined by Weak Clinical Validation and ELEVIDYS Sales Risk
1M ago
SRPT
Sarepta Therapeutics: Early TRiM Platform Promise Outweighed by High Clinical Risk and Valuation Downside, Justifying Sell Rating
Premium
Ratings
Sarepta Therapeutics: Early TRiM Platform Promise Outweighed by High Clinical Risk and Valuation Downside, Justifying Sell Rating
1M ago
SRPT
Sarepta price target raised to $13 from $9 at Citi
PremiumThe Fly
Sarepta price target raised to $13 from $9 at Citi
1M ago
SRPT
Sarepta price target raised to $25 from $20 at Morgan Stanley
PremiumThe Fly
Sarepta price target raised to $25 from $20 at Morgan Stanley
1M ago
SRPT
Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
PremiumThe Fly
Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
1M ago
GM
AMD
Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink
PremiumThe Fly
Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink
1M ago
SRPT
Sarepta early DM1 data ‘appear promising,’ says Oppenheimer
PremiumThe FlySarepta early DM1 data ‘appear promising,’ says Oppenheimer
1M ago
SRPT
Sarepta announces first clinical data from pipeline targeting FSHD1, DM1
Premium
The Fly
Sarepta announces first clinical data from pipeline targeting FSHD1, DM1
1M ago
SRPT
Guggenheim starts Solid Biosciences with a Buy on DMD gene therapy potential
Premium
The Fly
Guggenheim starts Solid Biosciences with a Buy on DMD gene therapy potential
1M ago
SLDB
SRPT
Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer
PremiumThe Fly
Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer
1M ago
SRPT
Sarepta provides regulatory update on Amondys 45, Vyondys 53
PremiumThe Fly
Sarepta provides regulatory update on Amondys 45, Vyondys 53
1M ago
SRPT
Sarepta begins screening, enrollment in Cohort 8 of ENDEAVOR study
PremiumThe Fly
Sarepta begins screening, enrollment in Cohort 8 of ENDEAVOR study
2M ago
SRPT
Carvana, Warner Bros, Axon, Energy Fuels, Sarepta Insider Shakeup
PremiumWeekend Updates
Carvana, Warner Bros, Axon, Energy Fuels, Sarepta Insider Shakeup
2M ago
WBD
AXON
Sarepta price target raised to $31 from $26 at Mizuho
PremiumThe FlySarepta price target raised to $31 from $26 at Mizuho
2M ago
SRPT
Sarepta price target raised to $9 from $8 at Citi
Premium
The Fly
Sarepta price target raised to $9 from $8 at Citi
2M ago
SRPT
Controversial Prasad leaving FDA, NYT reports
Premium
The Fly
Controversial Prasad leaving FDA, NYT reports
2M ago
AZN
BMY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >